Pimecrolimus
- Generic Name
- Pimecrolimus
- Brand Names
- Elidel
- Drug Type
- Small Molecule
- Chemical Formula
- C43H68ClNO11
- CAS Number
- 137071-32-0
- Unique Ingredient Identifier
- 7KYV510875
- Background
Pimecrolimus is an immunomodulating agent that was first marketed by Novartis under the trade name Elidel. It is now promoted in Canada by Galderma since early 2007. It is currently available as a topic cream used in the treatment of atopic dermatitis (eczema).
- Indication
For treatment of mild to moderate atopic dermatitis.
- Associated Conditions
- Vitiligo, Intertriginous psoriasis, Mild Atopic dermatitis, Moderate Atopic dermatitis
- Associated Therapies
- -
Steroid-Sparing Effect With Pimecrolimus in Pediatric Patients With Atopic Dermatitis
- First Posted Date
- 2006-07-12
- Last Posted Date
- 2008-01-17
- Lead Sponsor
- Novartis
- Target Recruit Count
- 184
- Registration Number
- NCT00351052
Pimecrolimus Cream 1% in Adult Patients With Perioral Dermatitis
- First Posted Date
- 2005-10-04
- Last Posted Date
- 2008-01-17
- Lead Sponsor
- Novartis
- Target Recruit Count
- 124
- Registration Number
- NCT00232115
- Locations
- 🇩🇪
Novartis Pharmaceuticals, Nürnberg, Germany
Extension Study of Pimecrolimus Cream in Pediatric Patients With Atopic Dermatitis
- First Posted Date
- 2005-10-04
- Last Posted Date
- 2007-12-17
- Lead Sponsor
- Novartis
- Target Recruit Count
- 240
- Registration Number
- NCT00231998
- Locations
- 🇯🇵
This study is not being conducted in the United States, Various Cities, Japan
Standardized Time- and Score-oriented Treatment of Moderate and Severe Atopic Dermatitis
- Conditions
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2010-06-09
- Lead Sponsor
- Technische Universität Dresden
- Registration Number
- NCT00148746
- Locations
- 🇩🇪
Department of Dermatology, TU Dresden, Dresden, Germany
Comparison of Pimecrolimus Cream 1% Twice-Daily to Once-Daily Dosing in the Management of Atopic Dermatitis in Pediatric Subjects
- First Posted Date
- 2005-08-31
- Last Posted Date
- 2008-04-23
- Lead Sponsor
- Novartis
- Registration Number
- NCT00139581
- Locations
- 🇨🇭
This study is not being conducted in the United States, Novartis Pharma AG, Basel, Switzerland
Efficacy of Elidel Cream on Erosive Oral Lichen Planus
- Conditions
- First Posted Date
- 2005-08-15
- Last Posted Date
- 2008-05-23
- Lead Sponsor
- University Hospital Tuebingen
- Target Recruit Count
- 20
- Registration Number
- NCT00130572
- Locations
- 🇩🇪
University Hospital, Department of Dermatology, Tuebingen, Germany
Efficacy and Safety of Pimecrolimus Cream 1% in Patients (2 to 11 Years Old) With Mild to Moderate Facial Atopic Dermatitis
- First Posted Date
- 2005-08-15
- Last Posted Date
- 2008-01-15
- Lead Sponsor
- Novartis
- Target Recruit Count
- 200
- Registration Number
- NCT00130364
- Locations
- 🇺🇸
This study is not being conducted in the United States, Novartis Pharmaceuticals, New Jersey, United States
Safety and Efficacy of Pimecrolimus Ophthalmic Suspension in Patients With Moderate to Severe Keratoconjunctivitis Sicca
- First Posted Date
- 2005-08-09
- Last Posted Date
- 2020-05-27
- Lead Sponsor
- Novartis
- Target Recruit Count
- 440
- Registration Number
- NCT00128245
- Locations
- 🇺🇸
Novartis, East Hanover, New Jersey, United States
Safety and Efficacy of Pimecrolimus Cream 1% in Atopic Disease Modification
- First Posted Date
- 2005-07-28
- Last Posted Date
- 2011-03-23
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 1091
- Registration Number
- NCT00124709
- Locations
- 🇺🇸
Children's Medical Group, Hopewell Junction, New York, United States
🇺🇸Central Dermatology, St Louis, Missouri, United States
🇺🇸Rx R & D, Metarie, Louisiana, United States
Safety and Efficacy of Pimecrolimus Cream 1% in Mild to Moderate Head and Neck Atopic Dermatitis (AD) Patients
- First Posted Date
- 2005-07-21
- Last Posted Date
- 2008-01-15
- Lead Sponsor
- Novartis
- Target Recruit Count
- 200
- Registration Number
- NCT00121316
- Locations
- 🇨🇭
This study is not being conducted in the United States, Novartis Pharma AG, Switzerland
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.